Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions

Brain Research Bulletin

Volumn 84, Issue 3, 2011, Pages 215-223

  Chen, Li ^a   Liu, Jian ^a   Ali, Umar ^a   Gui, Zhen Hua ^a   Hou, Chen ^a   Fan, Ling Ling ^a   Wang, Yong ^a   Wang, Tao ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anxiety; Basolateral nucleus of amygdala; Extracellular recording; MPEP; Parkinson's disease

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; APOMORPHINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BASOLATERAL AMYGDALA; BRAIN DAMAGE; CELL LOSS; CONTROLLED STUDY; MALE; NERVE CELL; NEURON FIRING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY; TREATMENT DURATION;

AMYGDALA; ANIMALS; ANXIETY DISORDERS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; MALE; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 79951629457     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.01.005     Document Type: Article

References (54)

1. Aarsland D., Larsen J.P., Lim N.G., Janvin C., Karlsen K., Tandberg E., Cummings J.L. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1999, 67:492-496.
2. 5 antagonist MPEP. Brain Res. 2005, 1033:216-220.
3. Akirav I., Maroun M. The role of the medial prefrontal cortex-amygdala circuit in stress effects on the extinction of fear. Neural. Plast. 2007, 2007:1-11.
4. Arnold S.E., Hyman B.T., Van H.G., Damasio A.R. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophreniam. Arch. Gen. Psychiatry 1991, 48:625-632.
5. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 2000, 20:7871-7879.
6. Battaglia G., Busceti C.L., Pontarelli F., Biagioni F., Fornai F., Paparelli A., Bruno V., Ruggieri S., Nicoletti F. Protective role of Group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 2003, 45:155-166.
7. Bernardi G., Cherubini E., Marciani M.G., Mercuri N., Stanzione P. Responses of intracellularly recorded cortical neurons to the iontophoretic application of dopamine. Brain Res. 1982, 245:267-274.
8. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., Morgese M.G., Popoli P., Alleva E. Nonmotor symptoms in Parkinson's disease: investigating early phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 2008, 86:2050-2061.
9. Breysse N., Amalric M., Salin P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 2003, 23:8302-8309.
10. Brodkin J., Busse C., Sukoff S.J., Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 2002, 73:359-366.
11. Brown A.S., Gershon S. Dopamine and depression. J. Neural. Transm. Gen. Sect. 1993, 91:75-109.
12. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 2000, 75:889-907.
13. Chen L., Zhang Q.J., Liu J., Wang S., Ali U., Gui Z.H., Wang Y. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons. Brain Res. 2009, 1286:192-200.
14. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
15. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J. Neural. Transm. Suppl. 1992, 36:61-89.
16. Fedrowitz M., Lindemann S., Loscher W., Gernert M. Altered spontaneous discharge rate and pattern of basal ganglia output neurons in the circling (ci2) rat mutant. Neuroscience 2003, 118:867-878.
17. Hamani C., Saint-Cyr J.A., Fraser J., Kaplitt M., Lozano A.M. The subthalamic nucleus in the context of movement disorders. Brain 2004, 127:4-20.
18. Lang E.J., Pare D. Synaptic responsiveness of interneurons of the cat lateral amygdaloid nucleus. Neuroscience 1998, 83:877-889.
19. Marco P., Simona P., Giuliano P., Miriam M., Luigi G.G., Lisa M.A. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 2004, 46:115-125.
20. Mason W.A., Capitanio J.P., Machado C.J., Mendoza S.P., Amaral D.G. Amygdalectomy and responsiveness to novelty in rhesus monkeys (Macaca mulatta): generality and individual consistency of effects. Emotion 2006, 6:73-81.
21. McDonald A.J., Beitz A.J., Larson A.A., Kuriyama R., Sellitto C., Madl J.E. Co-localization of glutamate and tubulin in putative excitatory neurons of the hippocampus and amygdala: an immunohistochemical study using monoclonal antibodies. Neuroscience 1989, 30:405-421.
22. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 2003, 70:83-244.
23. Muma N.A., Lee J.M., Gorman L., Heidenreich B.A., Mitrovic I., Napier T.C. 6-Hydroxydopamine-induced lesions of dopaminergic neurons alter the function of postsynaptic cholinergic neurons without changing cytoskeletal proteins. Exp. Neurol. 2001, 168:135-143.
24. Ni Z.G., Benazzouz R.B., Gao D.M., Benabid A.L., Benazzouz A. Time-course of changes in fi{ligature}ring rates and fi{ligature}ring patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res. 2001, 899:142-147.
25. Oades R.D., Taghzouti K., Rivet J.M., Simon H., Le Moal M. Locomotor activity in relation to dopamine and noradrenaline in the nucleus accumbens, septal and frontal areas: a 6-hydroxydopamine study. Neuropsychobiology 1986, 16:37-42.
26. Olanow C.W. Surgical therapy for Parkinson's disease. Eur. J. Neurol. 2002, 9(Suppl. 3):31-39.
27. 5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 2000, 131:1429-1437.
28. 5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001, 41:413-420.
29. Oueslati A., Breysse N., Amalric M., Kerkerian-Le G.L., Salin P. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur. J. Neurosci. 2005, 22:2765-2774.
30. Pare D. Role of the basolateral amygdala in memory consolidation. Prog. Neurobiol. 2003, 70:409-420.
31. Pare D., Gaudreau H. Projection cells and interneurons of the lateral and basolateral amygdala: distinct firing patterns and differential relation to theta and delta rhythms in conscious cats. J. Neurosci. 1996, 16:3334-3350.
32. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, California, USA. fourth ed.
33. Pérez de la Mora M., Lara-García D., Jacobsen K.X., Vázquez-García M., Crespo-Ramírez M., Flores-Gracia C., Escamilla-Marvan E., Fuxe K. Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety. Eur. J. Neurosci. 2006, 23:2749-2759.
34. Pirot S., Glowinski J., Thierry A.M. Mediodorsal thalamic evoked responses in the rat prefrontal cortex: influence of the mesocortical DA system. Neuroreport 1996, 7:1437-1441.
35. Rodgers R.J., Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci. Biobehav. Rev. 1997, 21:801-810.
36. Rosenkranz J.A., Grace A.A. Modulation of basolateral amygdala neuronal firing and afferent drive by dopamine receptor activation in vivo. J. Neurosci. 1999, 19:11027-11039.
37. Rosenkranz J.A., Grace A.A. Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J. Neurosci. 2002, 22:324-337.
38. Rouse S.T., Marino M.J., Bradley S.R., Awad H., Wittmann M., Conn P.J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther. 2000, 88:427-435.
39. Schrag A. Psychiatric aspects of Parkinson's disease - an update. J. Neurol. 2004, 251:795-804.
40. Schulz A., Fendt M., Gasparini F., Lingenhöhl K., Kuhn R., Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 2001, 41:1-7.
41. 2 dopamine receptors in the amygdaloid nuclear complex of the rat brain. Synapse 1992, 11:146-154.
42. Singewald N. Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neurosci. Biobehav. Rev. 2007, 31:18-40.
43. Spooren W.P., Gasparini F., Salt T.E., Kuhn R. Novel allosteric antagonists shed light on mGlu (5) receptors and CNS disorders. Trends Pharmacol. Sci. 2001, 22:331-337.
44. Spooren W.P., Vassout A., Neijt H.C., Kuhn R. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 2000, 295:1267-1275.
45. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da C.C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
46. Tatarczyńska E., Klodzińska A., Chojnacka-Wójcik E., Palucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 2001, 132:1423-1430.
47. Thomas L.S., Jane D.E., Gasparini F., Croucher M.J. Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology 2001, 41:523-527.
48. Tolosa E., Compta Y., Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:2-7.
49. Truong L., Allbutt H., Kassiou M., Henderson J.M. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav. Brain Res. 2006, 169:1-9.
50. Vernon A.C., Palmer S., Datla K.P., Zbarsky V., Croucher M.J., Dexter D.T. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur. J. Neurosci. 2005, 22:1799-1806.
51. 2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 2005, 1045:229-233.
52. Wang S., Zhang Q.J., Liu J., Wu Z.H., Ali U., Wang Y., Chen L., Gui Z.H. The firing activity of pyramidal neurons in medial prefrontal cortex and their response to 5-hydroxytryptamine-1A receptor stimulation in a rat model of Parkinson's disease. Neuroscience 2009, 162:1091-1100.
53. Wingerson D.K., Cowley D.S., Kramer G.L., Petty F., Roy-Byrne P.P. Effect of benzodiazepines on plasma levels of homovanillic acid in anxious patients and control subjects. Psychiatry Res. 1996, 65:53-59.
54. Ziemssen T., Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:323-332.